Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04784091
Recruitment Status : Recruiting
First Posted : March 5, 2021
Last Update Posted : November 5, 2021
Sponsor:
Information provided by (Responsible Party):
Tarsus Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.

Condition or disease Intervention/treatment Phase
Blepharitis Drug: TP-03 Drug: TP-03 Vehicle Phase 3

Detailed Description:
This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy of TP-03, 0.25% compared to its vehicle from Day 1 to Day 43 in adult participants with mild to severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy, endothelial cell density, hematology, blood chemistry, and urinalysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 418 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Active arm: TP-03, 0.25% Control arm: Vehicle of TP-03
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments.
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Actual Study Start Date : April 29, 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022

Arm Intervention/treatment
Experimental: Active
TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
Drug: TP-03
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day

Placebo Comparator: Control
Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
Drug: TP-03 Vehicle
Vehicle of TP-03 ophthalmic solution, administered twice a day




Primary Outcome Measures :
  1. The proportion of participants cured based on their collarette score [ Time Frame: 43 days ]

Secondary Outcome Measures :
  1. The proportion of participants with their Demodex mites eradicated [ Time Frame: 43 days ]
  2. The proportion of participants cured based on a composite of collarette score and erythema cure [ Time Frame: 43 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
  • Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash

Exclusion Criteria:

  • Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study
  • Have used a prostaglandin analogue to promote eyelash growth within 30 days of Screening or any plans to initiate treatment during the study
  • Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study
  • Be pregnant or lactating at the time of Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04784091


Contacts
Layout table for location contacts
Contact: Yesha Raval 978-685-8900 ext 9423 yraval@oraclinical.com
Contact: Jordan Janeiro 978-685-8900 ext 9436 jjaneiro@oraclinical.com

Locations
Show Show 21 study locations
Sponsors and Collaborators
Tarsus Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: John Meyer, MD The Eye Care Institute
Layout table for additonal information
Responsible Party: Tarsus Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04784091    
Other Study ID Numbers: TRS-010
First Posted: March 5, 2021    Key Record Dates
Last Update Posted: November 5, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tarsus Pharmaceuticals, Inc.:
Demodex
Additional relevant MeSH terms:
Layout table for MeSH terms
Blepharitis
Eyelid Diseases
Eye Diseases